Fig. 7. Antibodies and disease mutations at the ECR/7TM interface change the distributions of ADGRL3 holoreceptor conformations.

Schematic cartoon of the effects of sAB LK1 and cancer-associated mutations on conformational dynamics of ECR in ADGRL3. Activating sAB LK1 stabilizes the lower FRET states, while cancer mutants stabilize the higher FRET states of ADGRL3.